Carrageenan-induced acute inflammation in the mouse air pouch synovial model. Role of tumour necrosis factor

We used the mouse air pouch model of inflammation to study the interaction between cytokines, prostaglandin E2 (PGE2) and cell migration during the various phases of acute local inflammation induced by carrageenan. In serum, the levels of interleukin 1 (IL-1), interleukin 6 (IL-6), tumour necrosis factor (TNF), serum amiloid-A (SAA) and Fe++ were never different from controls, indicating that no systemic inflammatory changes were induced. Locally the exudate volume and the number of leukocytes recruited into the pouch increased progressively until 7 days after carrageenan. The same was true for PGE2 production. We could not measure IL-1 but the production of IL-6 and TNF reached a maximum after 5-24 h then quickly decreased. Anti-TNF antibodies inhibited cell migration by 50% 24 h after treatment. Pretreatment with interleukin 10 (IL-10) inhibited TNF production almost completely and cell migration by 60%. Carrageenan-induced inflammation was modulated by anti-inflammatory drugs. Pretreatment with dexamethasone (DEX) or indomethacin (INDO) inhibited cell migration and reduced the concentration of TNF in the exudate. Production of PGE2 or vascular permeability did not correlate with the number of cells in the pouch. Local TNF seems to play an important role in this model, particularly for leukocyte migration in the first phase of the inflammatory process. In conclusion, the air pouch seems to be a good model for studying the regulation of the early events of local inflammation, particularly the role of cytokines and cell migration.

[1]  J. A. Menius,et al.  Evaluation of the significance of elevated levels of systemic and localized tumor necrosis factor in different animal models of inflammation. , 1994, The Journal of laboratory and clinical medicine.

[2]  G. Fantuzzi,et al.  Defective inflammatory response in interleukin 6-deficient mice , 1994, The Journal of experimental medicine.

[3]  H. Okuyama,et al.  Regulation of lipopolysaccharide-induced tumor necrosis factor alpha production by endogenous prostaglandin E2 in rat resident and thioglycollate-elicited macrophages. , 1994, Journal of lipid mediators and cell signalling.

[4]  E. Pettipher,et al.  Cyclooxygenase inhibitors enhance tumour necrosis factor production and mortality in murine endotoxic shock. , 1994, Cytokine.

[5]  B. Vargaftig,et al.  Drug modulation of antigen‐induced paw oedema in guinea‐pigs: effects of lipopolysaccharide, tumour necrosis factor and leucocyte depletion , 1994, British journal of pharmacology.

[6]  J. Ghrayeb,et al.  Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. , 1993, Arthritis and rheumatism.

[7]  T. Smith-Oliver,et al.  Elevated levels of TNF in the joints of adjuvant arthritic rats. , 1993, Cytokine.

[8]  M. Howard,et al.  Interleukin 10 protects mice from lethal endotoxemia , 1993, The Journal of experimental medicine.

[9]  W. Fiers,et al.  Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia , 1993, The Journal of experimental medicine.

[10]  Yan Zhang,et al.  Neutrophil recruitment by tumor necrosis factor from mast cells in immune complex peritonitis. , 1992, Science.

[11]  D. Kioussis,et al.  Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. , 1991, The EMBO journal.

[12]  Remick Dg.  Significance of in vivo detection of tumor necrosis factor. , 1991 .

[13]  A. Mantovani,et al.  Protective effect of chlorpromazine on endotoxin toxicity and TNF production in glucocorticoid-sensitive and glucocorticoid-resistant models of endotoxic shock , 1991, The Journal of experimental medicine.

[14]  J. Sipe,et al.  Direct binding enzyme-linked immunosorbent assay (ELISA) for serum amyloid A (SAA). , 1989, Journal of immunological methods.

[15]  M. Feldmann,et al.  INHIBITORY EFFECT OF TNFα ANTIBODIES ON SYNOVIAL CELL INTERLEUKIN-1 PRODUCTION IN RHEUMATOID ARTHRITIS , 1989, The Lancet.

[16]  R. Strieter,et al.  Modulation of tumor necrosis factor-alpha gene expression. Desensitization of prostaglandin E2-induced suppression. , 1989, Journal of immunology.

[17]  D. Gemsa,et al.  Release of tumor necrosis factor-alpha from macrophages. Enhancement and suppression are dose-dependently regulated by prostaglandin E2 and cyclic nucleotides. , 1988, Journal of immunology.

[18]  R. Williams,et al.  Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis. , 1988, Journal of autoimmunity.

[19]  A. Meager,et al.  Cytokines in synovial fluid: II. The presence of tumour necrosis factor and interferon. , 1988, Clinical and experimental immunology.

[20]  D. Willoughby,et al.  Mast cells in newly formed lining tissue during acute inflammation: a six day air pouch model in the mouse. , 1986, Annals of the rheumatic diseases.

[21]  B. Beutler,et al.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. , 1985, Science.

[22]  S. Kunkel,et al.  Arachidonic acid metabolites regulate interleukin-1 production. , 1985, Biochemical and biophysical research communications.

[23]  D. Willoughby,et al.  Increased inflammatory reactivity in newly formed lining tissue , 1983, The Journal of pathology.

[24]  S Moncada,et al.  The release of leukotriene B4 during experimental inflammation. , 1983, Biochemical pharmacology.

[25]  I. Kushner.  THE PHENOMENON OF THE ACUTE PHASE RESPONSE * , 1982, Annals of the New York Academy of Sciences.

[26]  D. A. Willoughby,et al.  The formation of a structure with the features of synovial lining by subcutaneous injection of air: An in vivo tissue culture system , 1981, The Journal of pathology.